July 26, 2021
Meiji Seika Pharma and South Korean partner Dong-A ST have concluded a license pact to grant worldwide rights for their biosimilar version of Stelara (ustekinumab) to India’s Intas Pharmaceuticals, excluding Japan, South Korea, and certain Asian countries. According to a...read more